Parenteral exemption denied for vaginal suppositories; extended limitation also failed absent a properly pleaded suppression case.

Kemicetine vaginal suppositories were held not to be parenteral preparations because parenteral use requires administration beyond the alimentary canal with systemic absorption, whereas this product was used as a local or topical treatment for female genital tract infections. The claimed exemption under Notification No. 116/69-C.E. therefore failed. On limitation, the extended period was not sustainable because the show-cause notices and adjudication record did not clearly and specifically plead or prove fraud, suppression, or wilful misstatement. Recovery was accordingly confined to the normal limitation period.

---

---

Issues: (i) Whether kemicetine vaginal suppositories were parenteral preparations entitled to exemption under Notification No. 116/69-C.E. and its amending notification; (ii) whether the demand could be sustained for the extended period on the ground of suppression or misstatement of facts.

Issue (i): Whether kemicetine vaginal suppositories were parenteral preparations entitled to exemption under Notification No. 116/69-C.E. and its amending notification.

Analysis: The exemption applied to patent and proprietary medicines containing chloramphenicol for oral and parenteral use. The central question was the meaning of parenteral. The preparation was examined in the light of medical and pharmaceutical authorities. The word parenteral, in its accepted sense, denotes administration other than through the alimentary canal and, in the context of drug administration, contemplates introduction of the drug into the body fluids so that it has systemic effect. The material relied upon by the assessee showed that vaginal administration may in some situations permit absorption through the vaginal mucosa, but the evidence in this case showed that the product was used for local infections of the female genital tract and was described in the relevant material as local treatment. The preparation was therefore found to be a local or topical remedy rather than a parenteral one.

Conclusion: The preparation was not parenteral and was not entitled to the claimed exemption.

Issue (ii): Whether the demand could be sustained for the extended period on the ground of suppression or misstatement of facts.

Analysis: The show-cause notices did not allege fraud, suppression, or wilful misstatement with clarity, nor did they invoke penal consequences. The adjudication order asserted suppression, but without setting out concrete facts showing how such suppression or misstatement was established. In the absence of a properly pleaded and proved charge of suppression or misstatement, the longer period could not be upheld. The earlier assessments and approvals did not by themselves create a bar to lawful reassessment, but the extended limitation required a legally supported allegation of concealment or misstatement, which was not made out on the record.

Conclusion: The extended period was not sustainable, and recovery was confined to the normal limitation period.

Final Conclusion: The appeal failed on classification and exemption, but the demand was restricted to the normal period of six months before the notices.

Ratio Decidendi: A medicinal preparation is parenteral only if its administration is directed to systemic absorption beyond the alimentary canal; a product used merely for local or topical treatment does not qualify for parenteral exemption, and the extended period of recovery requires a clearly pleaded and proved case of suppression or misstatement.

---